Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 3,461 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intervention II Clear all
Completed Not applicable Interventional

Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer

NCT00080860
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, immunohistochemistry staining method, conventional surgery, lymphangiography, radionuclide imaging, sentinel lymph node biopsy, technetium Tc 99m sulfur colloid
Genetic · Other · Procedure + 1 more
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 23, 2026, 11:47 PM EDT
Enrolling by invitation No phase listed Observational

Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men

NCT06472817
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Phase 2 Interventional

Early Phase II Trials for Cocaine Medication Development - 1

NCT00000317
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Risperidone, Placebo, Relapse prevention counseling
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Phase 2 Interventional

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00416650
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

NCT00389818
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, prednisone, vincristine sulfate, immunohistochemistry staining method, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

NCT00073580
View directory record Official record
Conditions
Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 23, 2026, 11:47 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

NCT04282174
View directory record Official record
Conditions
Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
Interventions
CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine
Device · Procedure · Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
Up to 74 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 23, 2026, 11:47 PM EDT
Recruiting Phase 2 Interventional

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

NCT06013423
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging, Echocardiography, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

NCT04003246
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer Stage III
Interventions
Thoracic RT and Durvalumab, Consolidative Durvalumab
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662
View directory record Official record
Conditions
Breast Cancer
Interventions
HKI-272, Surgical Resection, Capecitabine, Ado-Trastuzumab Emtansine
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
18
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Not applicable Interventional

Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors

NCT01929720
View directory record Official record
Conditions
Anxiety Disorder, Worry, Uncertainty, Sleep Disorders, Insomnia, Fatigue, Pain, Depression, Cognitive-behavioral Therapy, Psychological Intervention, Esophageal Cancer, Pancreatic Cancer, Leukemia, Lung Cancer, Multiple Myeloma, Ovarian Neoplasm, Stage III or IV Cervical or Uterine Cancer, Stage IIIB, IIIC, or IV Breast Cancer, Glioblastoma Multiforme, Relapsed Lymphoma, Stage III or IV Colorectal Cancer, Stage IIIC or IV Melanoma
Interventions
Cognitive-behavioral therapy for worry, uncertainty & insomnia
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 23, 2026, 11:47 PM EDT
Terminated Not applicable Interventional

Primary Care-Based Physical Activity for Diabetic Latinas

NCT02741050
View directory record Official record
Conditions
Diabetes, Sedentary Lifestyle
Interventions
Tailored Physical Activity Intervention, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 23, 2026, 11:47 PM EDT
Active, not recruiting Not applicable Interventional

A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors

NCT06198010
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Best Practice, Educational Intervention, Questionnaire Administration, Electronic Health Record Review, Health Telemonitoring, Cancer Pain Management
Other · Procedure · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral Intervention in Reducing Indoor Tanning

NCT03448224
View directory record Official record
Conditions
Healthy Subject
Interventions
Questionnaire Administration, Internet-Based Intervention
Other
Lead sponsor
Jerod L Stapleton, PhD
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM

NCT00805961
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Radiation therapy, Temozolomide, Bevacizumab, Everolimus
Radiation · Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
13
States / cities
Huntsville, Alabama • Fort Myers, Florida • Gainesville, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 23, 2026, 11:47 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies

NCT05831540
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Discussion, Educational Activity, Healthcare Activity, Survey Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 23, 2026, 11:47 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

NCT02555189
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
Interventions
Enzalutamide, Ribociclib, Laboratory Biomarker Analysis, Pharmacological Study, Biospecimen Collection, Biopsy, Echocardiography, Multigated Acquisition Scan, Bone Scan, Computed Tomography, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Ann Arbor, Michigan • Buffalo, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo

NCT00258310
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
capecitabine, Surgery, chemotherapy and/or radiotherapy
Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Not applicable Interventional

Creative Arts II Study

NCT03994718
View directory record Official record
Conditions
Epilepsy
Interventions
Music intervention, Visual arts intervention, Creative writing intervention
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Not applicable Interventional

Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors

NCT03372720
View directory record Official record
Conditions
Cervical Carcinoma, Dyspareunia, Endometrial Carcinoma, Ovarian Carcinoma, Vaginal Carcinoma, Vaginal Dryness, Vulvar Carcinoma
Interventions
Laser Therapy, Questionnaire Administration, Sham Intervention
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Phase 1 Interventional

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation

NCT00705120
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide, Cyclosporin, Mesenchymal Stem Cell Transplantation, Busulfan
Other · Radiation · Drug + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2008 · Synced Oct 23, 2026, 11:47 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Sargramostim for Myeloid Dendritic Cell Deficiency

NCT03063242
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplant
Interventions
Sargramostim, Blood samples
Drug · Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 23, 2026, 11:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Conventional Infertility Treatment vs. Fast Track to IVF

NCT00260091
View directory record Official record
Conditions
Infertility
Interventions
intrauterine insemination, infertility
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years to 40 Years
Enrollment
503 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2006
U.S. locations
7
States / cities
Boston, Massachusetts • Brookline, Massachusetts • Burlington, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 23, 2026, 11:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial

NCT06926062
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Training and Education, Vaccination
Other · Behavioral · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
University Park, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 11:47 PM EDT